2. Search Result
Search Result
Results for "

embryonic carcinoma

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

3

Natural
Products

2

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2217
    Rotundic acid

    		Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid
  • HY-N6726
    Fumonisin B3

    		Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3
  • HY-P1684
    Peptide P60
    1 Publications Verification

    FOXP3 inhibitor P60

    		 NF-κB Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology Cancer
    Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
    Peptide P60
  • HY-15313C
    CBB1007 trihydrochloride
    2 Publications Verification

    		 Histone Demethylase Metabolic Disease Cancer
    CBB1007 trihydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
    CBB1007 trihydrochloride
  • HY-N6726S
    Fumonisin B3-13C34

    		Isotope-Labeled Compounds Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3- 13C34 is the 13C labeled Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3-13C34
  • HY-15313B
    CBB1007 hydrochloride

    		Histone Demethylase Metabolic Disease Cancer
    CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in  non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
    CBB1007 hydrochloride
  • HY-N6726R
    Fumonisin B3 (Standard)

    		Reference Standards Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3 (Standard) is the analytical standard of Fumonisin B3. This product is intended for research and analytical applications. Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3 (Standard)
  • HY-15313
    CBB1007

    		Histone Demethylase Metabolic Disease Cancer
    CBB1007 is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
    CBB1007
  • HY-N6726S1
    Fumonisin B3-13C34-1

    		Isotope-Labeled Compounds Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3-13C34-1 is the isotopic internal standard of Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3-13C34-1
  • HY-181116
    Anticancer agent 298

    		CDK Cancer
    Anticancer agent 298 is a bi-nuclear Cu(II)-hydrazone complexe. Anticancer agent 298 can bind to the CDK-2 active site (PDB ID: 3IG7) via hydrogen bonds with key amino acid residues. Anticancer agent 298 exerts cytotoxic effects against hepatocellular carcinoma cells, and has lower cytotoxicity against normal human embryonic kidney cells. Anticancer agent 298 can be used for the research of hepatocellular carcinoma .
    Anticancer agent 298
  • HY-183698
    CDK9-IN-51

    		CDK Cancer
    CDK9-IN-51 is a CDK9 inhibitor. CDK9-IN-51 binds stably to purified CDK9 protein via interactions with key active-site residues Cys106, Asp109, and Phe103. CDK9-IN-51 exhibits antiproliferative activity against multiple cancer cells. CDK9-IN-51 can be used for the research of cancer, such as lung carcinoma, cervical carcinoma and breast carcinoma .
    CDK9-IN-51
  • HY-181923
    IMP-Zn

    		EGFR CDK Cytochrome P450 Cancer
    IMP-Zn is a pyrazole-hydrazone Schiff base zinc (II) complex. IMP-Zn exhibits significant antiproliferative activity against human colorectal cancer cells and induces cell cycle arrest. IMP-Zn shows stronger binding affinity than its free ligand IMP towards three cancer-related protein targets: EGFR kinase 1M17, cytochrome P450 3RUK, and CDK inhibitor 6GUE. IMP-Zn can be used in studies related to colorectal cancer .
    IMP-Zn
  • HY-135146G
    GSK-3484862

    		DNA Methyltransferase Apoptosis Cancer
    GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
    GSK-3484862
  • HY-183788
    EGFR-IN-212

    		EGFR Apoptosis Cancer
    EGFR-IN-212 is an EGFR inhibitor with human IC50 values of 1.83 μM. EGFR-IN-212 reduces EGFR mRNA expression and induces apoptosis. EGFR-IN-212 can be used for the research of non-small cell lung carcinoma .
    EGFR-IN-212
  • HY-182510
    NTZ-24

    		STAT Interleukin Related Apoptosis Cancer
    NTZ-24 is a selective STAT3 pathway inhibitor. NTZ-24 suppresses STAT3 phosphorylation at Tyr705, blocks STAT3-DNA interaction, and downregulates the levels of STAT3 downstream target proteins. NTZ-24 induces cell-cycle arrest and promotes apoptosis in cancer cells. NTZ-24 exerts significant antiproliferative activity against HeLa cells (IC50 = 3.3 μM). NTZ-24 can be used for the research of cervical cancer .
    NTZ-24
  • HY-182266
    FBP

    		Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cancer
    FBP is a mitochondria-targeted, selective anticancer agent. FBP induces oxidative stress and mitochondrial dysfunction, leading to Apoptosis. FBP generates ROS and causes double-strand DNA breaks in cancer cells. FBP exhibits cytotoxic efficacy against cancer cells, with cervical cancer cells being the most sensitive. FBP can be used for the research of cervical cancer, lung cancer, melanoma and breast cancer .
    FBP

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: